Number of Shares and Voting Rights of ADOCIA as of May 31
Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31 st, 2025.
(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 minutes ago
- Business Wire
Take 2 R&S LLC Positioned as Industry Leader as California Mandates Safety Advisors in Film & TV Tax Credit Program
LOS ANGELES--(BUSINESS WIRE)--With the California Film Commission's recent enhancement to its Film & Television Tax Credit Program, mandating Safety Advisors on qualifying productions, Take 2 R&S LLC is proud to announce its readiness to meet this critical industry need with unparalleled expertise, infrastructure, and talent. Effective immediately, all productions receiving the California Tax Incentive must now retain Safety Advisors to oversee compliance with set safety protocols. This move—designed to elevate health and safety standards—mirrors longstanding studio-level expectations and aims to protect cast and crew across all production environments. Take 2 R&S LLC, a trusted partner in risk and safety management, is the only firm in California uniquely positioned to fulfill this mandate at scale. The company offers a turnkey solution modeled after major studio safety departments, combining decades of hands-on experience with a robust roster of certified professionals. 'This new requirement aligns perfectly with what we've been doing for years,' said Michael Tamburro, Founder of Take 2 R&S LLC. 'Our team doesn't just check boxes—we integrate safety into the culture of each production. We've built a structure that mirrors the major studios and can scale immediately to support both indie and large-scale projects.' Take 2's Safety Advisors are more than compliance officers—they are production veterans with specialized training in film and television safety standards, OSHA protocols, and incident prevention. The company supports clients with: On-set Safety Advisors tailored to each project's scale and complexity Studio-style infrastructure including incident reporting systems, site inspections, and daily safety briefings Close collaboration with producers, line staff, and labor unions to meet and exceed state mandates As Hollywood adapts to this evolving regulatory landscape, Take 2 R&S LLC is already delivering proactive, trusted solutions—ensuring productions remain eligible for tax incentives while protecting the people who bring stories to life.
Yahoo
29 minutes ago
- Yahoo
Kepler Capital Maintained a Buy Rating on Genfit (GNFT)
Genfit S.A. (NASDAQ:GNFT) is one of the . On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40. The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at 2,673 and 1,894, respectively. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases. While we acknowledge the potential of GNFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Bloomberg
2 hours ago
- Bloomberg
Cinven Confirms Exclusive Talks for Data Services Firm Artefact
Private equity firm Cinven is in exclusive negotiations to acquire Artefact, a provider of data and artificial intelligence consulting services. The transaction is subject to regulatory approvals, according to a statement on Monday that confirmed an earlier Bloomberg News report. While financial terms weren't disclosed, people familiar with the matter have said the deal could value the French company at about €1 billion ($1.2 billion).
